Karyopharm Therapeutics: chief accounting officer Kristin Abate sold 378 shares

What happened

• Kristin Abate, chief accounting officer, sold 378 shares at $1.19 per share on Oct 01, 2026, totaling $450.
• The filing describes the sale as a broker-assisted transaction to satisfy tax withholding upon the vesting of restricted stock units.

Key details

• Transaction date and price: Oct 01, 2026 — 378 shares at $1.19.
• Total proceeds: $450.
• Shares owned after the transaction: not reported in the filing.
• Footnote: the sale was effected under a durable automatic sale instruction plan adopted May 27, 2021, and represents a broker-assisted sale to satisfy withholding tax liability on vested restricted stock units; the sale does not represent a discretionary trade by the reporting person.
• Filing date: Oct 02, 2026.

Why it may matter

• This was a broker-assisted sale to cover tax withholding for vested restricted stock units, not an option exercise or a gift.
• A filing does not show why the insider traded or why the company acted.